BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/2/2022 12:11:47 PM | Browse: 423 | Download: 954
 |
Received |
|
2021-11-22 20:13 |
|
Peer-Review Started |
|
2021-11-22 20:14 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-27 01:22 |
|
Revised |
|
2022-01-09 21:54 |
|
Second Decision |
|
2022-04-14 02:11 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-04-21 18:05 |
|
Articles in Press |
|
2022-04-21 18:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-20 08:21 |
|
Publish the Manuscript Online |
|
2022-06-02 12:11 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Updates in therapeutic drug monitoring in inflammatory bowel disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nilesh Lodhia and Shanti Rao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nilesh Lodhia, MD, Associate Professor, Department of Gastroenterology and Hepatology, Atrium Health, CHS Digestive Health 1025 Morehead Medical Drive, Suite 300, Charlotte, NC 28203, United States. nilesh.lodhia@atriumhealth.org |
| Key Words |
Inflammatory bowel disease; Therapeutic drug monitoring; Crohn’s disease; Ulcerative colitis |
| Core Tip |
Inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn’s disease, are best treated with immunomodulators (IMM) or biologics. The rate of response clinically and endoscopically varies between the medications and within patient populations. Therapeutic drug monitoring (TDM) is a useful technique to assess drug and metabolite levels as well as anti-drug levels in patients on biologics or IMM in order to improve clinical outcome and prevent a multitude of complications. Here we discuss the role of TDM in patients with IBD with a focus on reactive vs proactive TDM. |
| Publish Date |
2022-06-02 12:11 |
| Citation |
Lodhia N, Rao S. Updates in therapeutic drug monitoring in inflammatory bowel disease. World J Gastroenterol 2022; 28(21): 2282-2290 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i21/2282.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i21.2282 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
